MedTrace Logo

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

NCT02772198 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-11-03

No results posted yet for this study

Summary

This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.

Conditions

  • Acute Lymphoblastic Leukemia, B-precursor
  • Non-Hodgkin Lymphoma, B-cell

Interventions

BIOLOGICAL

CD19 CAR T cells

Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19

Sponsors & Collaborators

  • Sheba Medical Center

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2022-07-31
Completion
2022-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772198 on ClinicalTrials.gov